In 2021, it is standard of care to use one of the new androgen receptor inhibitors (ARIs) in high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
This has a major impact on time to metastases and even better on survival, based on the 3 randomised clinical trials. However, several questions remain:
- Which patients will truly benefit?
- How do we choose among the 3 available drugs and what about their impact on Quality of Life?
- What is the real value, if any, of the new imaging modalities?
The purpose of this UROwebinar is to clarify these questions to improve our daily practice which will lead to the delivery of optimal care.